Remogliflozin etabonate

Drug Profile

Remogliflozin etabonate

Alternative Names: 189075; BHV 091009; GSK 189075; KGT-1681; Remo; Remogliflozin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kissei Pharmaceutical
  • Developer BHV Pharma
  • Class Antihyperglycaemics; Glucosides; Pyrans; Pyrazoles
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Phase I Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 12 Jan 2017 BHV Pharma completes a phase II trial for Type-2 diabetes mellitus in USA (NCT02537470)
  • 23 May 2016 No recent reports on development identified - Phase-II for Type-2 diabetes mellitus (Combination therapy) in USA (PO)
  • 23 May 2016 Phase-IIb clinical trials in Non-alcoholic steatohepatitis in USA (PO) before May 2016 (BHV Pharma website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top